<code id='EB78F17997'></code><style id='EB78F17997'></style>
    • <acronym id='EB78F17997'></acronym>
      <center id='EB78F17997'><center id='EB78F17997'><tfoot id='EB78F17997'></tfoot></center><abbr id='EB78F17997'><dir id='EB78F17997'><tfoot id='EB78F17997'></tfoot><noframes id='EB78F17997'>

    • <optgroup id='EB78F17997'><strike id='EB78F17997'><sup id='EB78F17997'></sup></strike><code id='EB78F17997'></code></optgroup>
        1. <b id='EB78F17997'><label id='EB78F17997'><select id='EB78F17997'><dt id='EB78F17997'><span id='EB78F17997'></span></dt></select></label></b><u id='EB78F17997'></u>
          <i id='EB78F17997'><strike id='EB78F17997'><tt id='EB78F17997'><pre id='EB78F17997'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:leisure time    Page View:3
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In